166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC). (13th May 2019) - Tripathy, D; Hortobagyi, G N; Chan, A; Im, S-A; Chia, S; Yardley, D; Esteva, F J; Hurvitz, S A; Ridolfi, A; Slamon, D